Search research articles
Contact Us
Filters
Showing results (121-130 of 143) with videos related to
Page
of 15
Sort By:
British Journal of Cancer
|
August 2, 2006
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T Eisen, T Ahmad, K T Flaherty, et al.
Physics in Medicine and Biology
|
March 24, 2021
Synthetic CT for single-fraction neoadjuvant partial breast irradiation on an MRI-linac
M L Groot Koerkamp, Y J M de Hond, M Maspero, et al.
Transplantation and Cellular Therapy
|
June 17, 2026
Real-world assessment of prophylactic anakinra on neurotoxicity and cytokine release syndrome after CD19 CAR T-cell therapy in R/R B-cell lymphoma: An inverse probability of treatment weighting analysis
Neela Easton, Mia Andreoli, Herman van Besien, et al.
Cancer Discovery
|
February 1, 2015
The genetics of splicing in neuroblastoma
Justin Chen, Christopher S Hackett, Shile Zhang, et al.
Cell Reports
|
May 29, 2026
Tumor-intrinsic expression of signal regulatory protein α contributes to the suppression of anti-tumor immune responses
Chien-Huan Weng, Chana Schochet, Vincent Panneton, et al.
Journal of Clinical Immunology
|
February 10, 2015
Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe
A J Turley, B Gathmann, C Bangs, et al.
Journal of the National Cancer Institute
|
October 17, 2002
Serum proteomic patterns for detection of prostate cancer
Emanuel F Petricoin, David K Ornstein, Cloud P Paweletz, et al.
Biorxiv : the Preprint Server for Biology
|
March 11, 2024
CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit
Fei Yi, Tal Cohen, Natalie Zimmerman, et al.
Cancer Research
|
October 22, 2009
Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality
Lara S Collier, David J Adams, Christopher S Hackett, et al.
Nature Medicine
|
September 28, 2010
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma
Alexander Swarbrick, Susan L Woods, Alexander Shaw, et al.
Page
of 15
Search research articles
Search
Showing results (121-130 of 143) with videos related to
Sort By:
Page
of 15
British Journal of Cancer
|
August 2, 2006
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T Eisen, T Ahmad, K T Flaherty, et al.
Physics in Medicine and Biology
|
March 24, 2021
Synthetic CT for single-fraction neoadjuvant partial breast irradiation on an MRI-linac
M L Groot Koerkamp, Y J M de Hond, M Maspero, et al.
Transplantation and Cellular Therapy
|
June 17, 2026
Real-world assessment of prophylactic anakinra on neurotoxicity and cytokine release syndrome after CD19 CAR T-cell therapy in R/R B-cell lymphoma: An inverse probability of treatment weighting analysis
Neela Easton, Mia Andreoli, Herman van Besien, et al.
Cancer Discovery
|
February 1, 2015
The genetics of splicing in neuroblastoma
Justin Chen, Christopher S Hackett, Shile Zhang, et al.
Cell Reports
|
May 29, 2026
Tumor-intrinsic expression of signal regulatory protein α contributes to the suppression of anti-tumor immune responses
Chien-Huan Weng, Chana Schochet, Vincent Panneton, et al.
Journal of Clinical Immunology
|
February 10, 2015
Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe
A J Turley, B Gathmann, C Bangs, et al.
Journal of the National Cancer Institute
|
October 17, 2002
Serum proteomic patterns for detection of prostate cancer
Emanuel F Petricoin, David K Ornstein, Cloud P Paweletz, et al.
Biorxiv : the Preprint Server for Biology
|
March 11, 2024
CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit
Fei Yi, Tal Cohen, Natalie Zimmerman, et al.
Cancer Research
|
October 22, 2009
Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality
Lara S Collier, David J Adams, Christopher S Hackett, et al.
Nature Medicine
|
September 28, 2010
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma
Alexander Swarbrick, Susan L Woods, Alexander Shaw, et al.
Page
of 15